Nektar Therapeutics (NKTR) FCF Margin (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly FCF Margin of 408.03% for Q1 2026, up 6095.0% year-over-year from 6.59% in Q1 2025, and down 36.94% quarter-over-quarter from 297.96% in Q4 2025.
Powered by 
Analysis
Nektar Therapeutics (NKTR) FCF Margin (2010 - 2026) Analysis & Trends
Nektar Therapeutics' FCF Margin history runs 17 years deep, the most recent figure standing at 408.03% for Q1 2026.
- In Q1 2026, FCF Margin rose 6095.0% year-over-year to 408.03%; the TTM figure through Mar 2026 stood at 366.59% (down 16236.0% YoY), while the FY2025 annual figure was 377.83%, down 19782.0% from the prior year.
- FCF Margin for Q1 2026 stood at 408.03%, down from 297.96% in the prior quarter.
- The five-year high for FCF Margin was 159.88% in Q4 2024, with the low at 468.98% in Q1 2025.
- The 5-year median for FCF Margin is 264.34% (2022), against an average of 290.26%.
- The sharpest annual moves came in 2022 and 2025: FCF Margin soared 36517 bps in 2022, then plunged 24832 bps in 2025.
- Nektar Therapeutics' FCF Margin stood at 264.34% in 2022, then advanced by 25 bps to 197.97% in 2023, then grew by 19 bps to 159.88% in 2024, then sank by 86 bps to 297.96% in 2025, then plunged by 37 bps to 408.03% in 2026.
- Business Quant data shows NKTR's FCF Margin at 408.03% in Q1 2026, 297.96% in Q4 2025, and 414.55% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn | -748.83% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -748.83% |
| Mar 31, 2026 | -408.03% |
| Dec 31, 2025 | -297.96% |
| Sep 30, 2025 | -414.55% |
| Jun 30, 2025 | -409.62% |
| Mar 31, 2025 | -468.98% |
| Dec 31, 2024 | -159.88% |
| Sep 30, 2024 | -184.87% |
| Jun 30, 2024 | -161.30% |
| Mar 31, 2024 | -222.03% |
| Dec 31, 2023 | -197.97% |
| Sep 30, 2023 | -174.59% |
| Jun 30, 2023 | -252.13% |
| Mar 31, 2023 | -242.42% |
| Dec 31, 2022 | -264.34% |
| Sep 30, 2022 | -351.61% |
| Jun 30, 2022 | -351.04% |
| Mar 31, 2022 | -373.16% |
| Dec 31, 2021 | -629.51% |
| Sep 30, 2021 | -417.61% |